Less-invasive BPH (benign prostatic hyperplasia) treatment cleared for US sale:
This article was originally published in Clinica
Executive Summary
The US FDA has cleared for sale Gyrus' Endourology system, which uses PlasmaKinetic radiofrequency technology to remove part of the prostate in patients with benign prostatic hyperplasia. The system is the third using PlasmaKinetic technology to be cleared by the FDA - the VAPR arthroscopy device and the VersaPoint hysteroscopic system are already sold in that market. The Cardiff, UK-based company now plans to begin discussions with potential US distributors for the Endourology system.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.